

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**March 6, 2019**  
**MINUTES**

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, March 6, 2019.

**2. Welcome**

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Divya Ahuja, MD  
Philip Mubarak, MD  
Gregory Browning, MD

Edward Behling, MD  
Duncan Norton, MD  
Kelli Savia, MD

Joni Bollinger, MD  
Erika Tillery, PharmD

**SC DHHS Staff:**

Jim Bradford, MD  
Bryan Amick, PharmD  
William Wynn, PharmD  
Constance Holloway, JD  
Janet Giles

**Magellan Medicaid Admin:**

Lisa Correll, PharmD  
Lori Ash

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, June 6, 2018**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. Public Comment**

Company	Speaker	Drug/Class
Indivior	Nick Casale, PharmD, MS, MBA	Perseris
Alkermes	Anthony Richards, PharmD	Aristada Initio
Otsuka	James Swartz, Rph, MBA	Abilify Maintenna

**C. Drug Classes for Review**

Lisa Correll led the discussion for the following drug classes:

*Class for Re-Review*

Long Acting Injectable Antipsychotics (2<sup>nd</sup> Generation)

The chart below represents the recommendations from the P & T Committee:

LONG ACTING INJECTABLE ANTIPSYCHOTICS (2 <sup>ND</sup> GENERATION)	
Preferred	Non-Preferred
Abilify Maintenna	Zyprexa Relprev
Aristada	
Aristada Initio‡	
Invega Sustenna/Trinza	
Perseris‡	
Risperdal Consta	

‡ Indicates “Added as Preferred”

+ Indicates “Moved to Non-Preferred”

**5. Old Business**

None

**6. New Business**

Lisa presented new drugs to market. Bryan introduced William Wynn, PharmD, as SC’s new Pharmacy Director and welcomed the new P&T Committee members. Bryan provided an overview of current SC Medicaid statistics, SC initiatives to address opioid and substance abuse disorders, the expenditure trend of Hepatitis C treatment from Q1 2013 through the present and the “Community Engagement Waiver”(Sec 1115 Demo Waiver). The waiver is open for public comment with 6 public hearings planned. Target date of July 2020 for Go Live.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

*Class for Re-Review*

Long Acting Injectable Antipsychotics (2<sup>nd</sup> Generation)

8. **Closing Comments**

The next meeting date to be determined.

9. **Adjournment**

The meeting adjourned at 5:06 p.m.